January 21, 2025 - 00:35

A recent study examining data from more than 2 million veterans has revealed that GLP-1 receptor agonists, commonly known for their use in weight loss, offer notable benefits for brain health. These medications, including well-known brands like Ozempic and Wegovy, have been linked to a decreased risk of various neurological conditions, such as addiction, Alzheimer’s disease, and dementia.
The findings suggest that these drugs may play a significant role in enhancing behavioral health, potentially providing a dual benefit for individuals seeking weight management solutions while also safeguarding cognitive function. However, the study also raises concerns about potential health risks associated with long-term use of GLP-1 receptor agonists. As the popularity of these medications continues to grow, it is essential for healthcare professionals and patients alike to weigh the benefits against the potential drawbacks. Ongoing research will be crucial to fully understand the long-term implications of these treatments on overall health and well-being.
February 26, 2026 - 20:57
Austin PD focuses on officers’ mental health supportRecognizing the unique and cumulative stresses of police work, the Austin Police Department is significantly enhancing its support systems for officer mental health. The initiative provides a...
February 26, 2026 - 03:32
NYC Health + Hospitals Named One Of The Top Places To Work In Healthcare By Becker's Healthcare - NYC Health + HospitalsNYC Health + Hospitals, the largest public healthcare system in the United States, has been honored as one of the premier workplaces in the American healthcare industry for the coming year. The...
February 25, 2026 - 10:44
Rep. Edwards, Smith discuss their positions on health careWith just six days to go before primary election day, voters are presented with a stark choice on one of the nation`s most pressing issues: healthcare. The positions of the leading candidates...
February 24, 2026 - 19:44
Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial missNew clinical trial results for the promising obesity treatment CagriSema have delivered a surprise outcome, with the drug failing to outperform a key rival in a closely watched study. The...